Medtronic invests millions in NanoCor

TriMed Staff | | Health Imaging | Cardiac Imaging
Medtronic has invested $3.75 million in biotechnology company NanoCor Therapeutics of Chapel Hill, N.C., which intends to use the investment to develop and commercialize a gene therapy for congestive heart failure (CHF). Medtronic has also agreed to invest an additional $3.75 million upon NanoCor meeting certain CHF milestones.

As part of the investment, Medtronic has acquired certain rights to exclusively license NanoCor’s CHF therapeutic, which consists of the delivery of a proprietary gene developed at the Massachusetts General Hospital and the University of Cincinnati.

This technology was developed at the University of North Carolina at Chapel Hill and originally exclusively licensed to Asklepios BioPharmaceutical, an affiliate of Nanocor.

TriMed Staff

Related Content

Global shortage of nuclear imaging isotopes may be over
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT
FDA clears AI tool that flags signs of heart disease in chest CT scans
AI-enabled plaque assessments help cardiologists ID high-risk CAD patients
Abbott CGM sensors can now be worn during common imaging procedures
New data highlight long-term benefits of HeartFlow’s AI-based CAD evaluations

Around the web

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business
FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup